Insights from C. elegans screening with SydLab™ One
Discover how ElixIRA Pharma leveraged high-throughput in vivo screening to evaluate the synergistic effects of two compounds (E1 and E2) on lifespan, motility, and biological age, using automated and AI-driven analysis.
What you’ll learn:
- How integrating phenotypic readouts early can de-risk candidate selection by identifying efficacy and toxicity trends before vertebrate studies.
- How multi-endpoint in vivo data helps uncover compound synergies, dose optimization, and mechanistic insights that traditional assays can’t capture.
- How quantitative lifespan, healthspan, and biological-age data can speed up go/no-go decisions and strengthen translational confidence.
- How automated, reproducible in vivo testing can compress timelines between discovery, preclinical validation, and IND-enabling studies.
The results speak for themselves: significant lifespan extension and motility improvements, with early biological age reductions detected by the Nagi™ B-Age assay (see visual data on page 4 of the use case).
